University of California, Riverside Assistant Professor of Bioengineering, Jiayu Liao played a pivotal role in the discovery of a small molecule that has been shown to control diabetes in mice and may pave the way to the development of easier treatment for adult-onset diabetes.
This discovery was a collaboration between Liao at UC Riverside's Bourns College of Engineering and a team in the National Center for Drug Screening, Shanghai, which is part of the Chinese Academy of Science.
This key molecule, identified as Boc5, can stimulate insulin function in response to high levels of glucose as well as reduce body weight by 20 percent. The discovery of this molecule that stimulates the production of the intestinal hormone glucagon-like peptide1 (GLP1), which metabolizes glucose, has been an extremely difficult goal for researchers in both academics and the pharmaceutical industry.
Boc5 is the first small molecule activator for Class B GPCRs, which regulate hormones in many human physiological processes and are major targets for pharmaceutical companies. This discovery opened new revenue possibilities to support future research into small molecule interaction with Class B GPCRs in the future.
In the study, Liao and his colleagues were looking for ways to sensitize sugar-metabolizing insulin by stimulating production of GLP1. Synthetic versions of this peptide have proven effective but of short duration so it had been abandoned by drug researchers.
However, after Liao and his colleagues screened a library of more than 48,000 natural and synthetic compounds, they identified a molecule, Boc5, which mimics glucagon-like peptide1 in the blood leading to increases in insulin secretion in laboratory cultured rat pancreatic cells when exposed to high glucose levels. The molecule also worked when administered by injection and orally in experiments with laboratory mice.
Thus Boc5 behaved as full GLP1 mimic, both in the test tube and in the laboratory mice, the researchers reported in an article that appeared in the Jan. 16 edition of the Proceedings of the National Academies of Science titled “A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.”
The fact that the molecule also lowered appetite and promoted weight loss in mice, holds out the promise it may fuel more exploration of orally available insulin sensitizing drugs that can be used to control diabetes and obesity, the article’s authors wrote.
Ricardo Duran | EurekAlert!
Gut microbiome regulates the intestinal immune system, researchers find
19.12.2018 | Brown University
Greener days ahead for carbon fuels
19.12.2018 | DOE/Lawrence Berkeley National Laboratory
Different eras of civilization are defined by the discovery of new materials, as new materials drive new capabilities. And yet, identifying the best material...
Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.
Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
19.12.2018 | Materials Sciences
19.12.2018 | Materials Sciences
19.12.2018 | Life Sciences